Rhythm Pharmaceuticals diskutieren
Rhythm Pharmaceuticals
WKN: A2H5A0 / Symbol: RYTM / Name: Rhythm Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
98,50 €
12,57 %
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $64.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $64.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $64.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $70.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $64.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $55.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Needham & Company LLC from $55.00 to $64.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at TD Cowen from $55.00 to $65.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at HC Wainwright from $64.00 to $69.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $69.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $59.00 to $66.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $76.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $69.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $80.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $64.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $64.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at HC Wainwright from $69.00 to $70.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $78.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $72.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Neueste Beiträge
StockNews_com in Axcelis Technologies diskutieren